Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fennec Pharmaceuticals (FENC) Share-based Compensation (2016 - 2025)

Historic Share-based Compensation for Fennec Pharmaceuticals (FENC) over the last 15 years, with Q3 2025 value amounting to $2.2 million.

  • Fennec Pharmaceuticals' Share-based Compensation rose 2185.61% to $2.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.6 million, marking a year-over-year increase of 1754.28%. This contributed to the annual value of $5.1 million for FY2024, which is 547.25% down from last year.
  • According to the latest figures from Q3 2025, Fennec Pharmaceuticals' Share-based Compensation is $2.2 million, which was up 2185.61% from $1.5 million recorded in Q2 2025.
  • Fennec Pharmaceuticals' 5-year Share-based Compensation high stood at $2.5 million for Q2 2023, and its period low was $399000.0 during Q1 2022.
  • Over the past 5 years, Fennec Pharmaceuticals' median Share-based Compensation value was $1.0 million (recorded in 2023), while the average stood at $1.2 million.
  • As far as peak fluctuations go, Fennec Pharmaceuticals' Share-based Compensation surged by 17293.23% in 2023, and later crashed by 6362.56% in 2024.
  • Over the past 5 years, Fennec Pharmaceuticals' Share-based Compensation (Quarter) stood at $917000.0 in 2021, then decreased by 9.81% to $827000.0 in 2022, then rose by 3.63% to $857000.0 in 2023, then surged by 31.16% to $1.1 million in 2024, then soared by 97.42% to $2.2 million in 2025.
  • Its Share-based Compensation stands at $2.2 million for Q3 2025, versus $1.5 million for Q2 2025 and $798000.0 for Q1 2025.